Please use this identifier to cite or link to this item:
Title: Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies
Authors: Sanchez-Garrido, Miguel A.
Tena-Sempere, Manuel
metadata.dc.contributor.authoraffiliation: [Sanchez-Garrido,MA; Tena-Sempere,M] Instituto Maimónides de Investigación Biomédica de Cordoba (IMIBIC), Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] Department of Cell Biology, Physiology, and Immunology, University of Cordoba, Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] Hospital Universitario Reina Sofia, Cordoba, Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III Cordoba, Spain. [Tena-Sempere,M] FiDiPro Program, Institute of Biomedicine, University of Turku, FIN-20520 Turku, Finland.
Keywords: PCOS;Androgen excess;Insulin resistance;Obesity;Poly-agonists;GLP-1;Síndrome del ovario poliquístico;Resistencia a la insulina;Obesidad;Péptido 1 similar al glucagón
metadata.dc.subject.mesh: Medical Subject Headings::Anatomy::Tissues::Connective Tissue::Adipose Tissue
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Androgens
Medical Subject Headings::Organisms::Eukaryota::Animals
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Bariatrics::Bariatric Surgery
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Diseases::Endocrine System Diseases::Gonadal Disorders::Disorders of Sex Development::Adrenogenital Syndrome::Hyperandrogenism
Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome X
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice
Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity
Medical Subject Headings::Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Genital Diseases, Female::Adnexal Diseases::Ovarian Diseases::Ovarian Cysts::Polycystic Ovary Syndrome
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Insulin Resistance
Issue Date: 5-Feb-2020
Publisher: Elsevier
Citation: Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020 May;35:100937
Abstract: Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive age women. Although its cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, PCOS women often display also notable metabolic comorbidities. An array of pathogenic mechanisms have been implicated in the etiology of this heterogeneous endocrine disorder; hyperandrogenism at various developmental periods is proposed as a major driver of the metabolic and reproductive perturbations associated with PCOS. However, the current understanding of the pathophysiology of PCOS-associated metabolic disease is incomplete, and therapeutic strategies used to manage this syndrome's metabolic complications remain limited. Scope of review:This study is a systematic review of the potential etiopathogenic mechanisms of metabolic dysfunction frequently associated with PCOS, with special emphasis on the metabolic impact of androgen excess on different metabolic tissues and the brain. We also briefly summarize the therapeutic approaches currently available to manage metabolic perturbations linked to PCOS, highlighting current weaknesses and future directions. Major conclusions:Androgen excess plays a prominent role in the development of metabolic disturbances associated with PCOS, with a discernible impact on key peripheral metabolic tissues, including the adipose, liver, pancreas, and muscle, and very prominently the brain, contributing to the constellation of metabolic complications of PCOS, from obesity to insulin resistance. However, the current understanding of the pathogenic roles of hyperandrogenism in metabolic dysfunction of PCOS and the underlying mechanisms remain largely incomplete. In addition, the development of more efficient, even personalized therapeutic strategies for the metabolic management of PCOS patients persists as an unmet need that will certainly benefit from a better comprehension of the molecular basis of this heterogeneous syndrome.
metadata.dc.identifier.doi: 10.1016/j.molmet.2020.01.001
ISSN: 2212-8778 (Online)
Appears in Collections:01- Artículos - Hospital Reina Sofía
01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba

Files in This Item:
File Description SizeFormat 
SanchezGarrido_MetabolicDysfunction.pdfRevisión sistemática1,23 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons